David Robert Hale

Partner at ValueAct Capital Management LP

David Robert Hale

David Robert Hale

Partner at ValueAct Capital Management LP

Biography

Mr. David R. Hale is Partner at ValueAct Capital Management LP. He is on the Board of Directors at Valeant Pharmaceuticals International, Inc. Prior to joining ValueAct Capital in January 2011, Mr. Hale was a Principal with The Parthenon Group, working in both the Boston and Mumbai offices of Parthenon’s strategic consulting practice, as well as in an investment role at Parthenon’s long-short public equity vehicle, Strategic Value Capital. He is a former director of MSCI, Inc. He has an A.B., cum laude, from Dartmouth College

Overview
RelSci Relationships

257

Number of Boards

2

Birthday

1985

Age

34

Contact Data
Trying to get in touch with David Robert Hale? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals David Robert Hale likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman of the Board & Chief Executive Officer at Bausch Health Cos., Inc.

Relationship likelihood: Strong

Founder at ValueAct Capital Management LP

Relationship likelihood: Strong

President & Chief Investment Officer at ValueAct Capital Management LP

Relationship likelihood: Strong

Former Director at Valeant Pharmaceuticals International Corp.

Relationship likelihood: Strong

US President at Bausch + Lomb, Inc.

Relationship likelihood: Strong

General Manager, Neuro & Other, Generics & Obagi at Bausch Health Cos., Inc.

Relationship likelihood: Strong

Director at Social Finance, Inc.

Relationship likelihood: Strong

Partner at Care Capital LLC

Relationship likelihood: Strong

Former Chief Financial Officer at Bank of Montreal

Relationship likelihood: Strong

General Counsel at ValueAct Capital Management LP

Relationship likelihood: Strong

Paths to David Robert Hale
Potential Connections via
Relationship Science
You
David Robert Hale
Partner at ValueAct Capital Management LP
Family Members
Parent-In-Law
Former Chief Executive Officer at Freddie Mac

Freddie Mac was chartered by Congress in 1970 with a public mission to stabilize the nation's residential mortgage markets and expand opportunities for homeownership and affordable rental housing. Our statutory mission is to provide liquidity, stability and affordability to the U.S. housing market. We participate in the secondary mortgage market by purchasing mortgage loans and mortgage-related securities for investment and by issuing guaranteed mortgage-related securities, principally those we call PCs. The secondary mortgage market consists of institutions engaged in buying and selling mortgages in the form of whole loans (i.e., mortgages that have not been securitized) and mortgage-related securities. We do not lend money directly to homeowners.

Education
A.B., cum laude

Founded in 1769, Dartmouth is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools—the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

Career History
Partner
2011 - Current

ValueAct Capital was initially formed in June 2000 to manage the capital of its three founders, along with the capital of a limited number of outside investors, in an investment strategy that combines intensive due diligence, a concentrated number of investments, and active, constructive involvement in the value creation at those investments. Today, with offices in San Francisco and Boston, ValueAct Capital manages more than $8.0 billion on behalf of some of the world's most respected institutional and individual investors. ValueAct Capital concentrates on acquiring significant ownership stakes in a limited number of companies that it believes are fundamentally undervalued. The investment team seeks to identify companies that are out of favor, or may be undergoing significant transition. Such companies may be temporarily mispriced for a variety of reasons, including perceived unfavorable industry conditions, poor business performance, changes in management or ownership, reorganizations, or other external factors. These conditions can often result in fundamentally "good" businesses that are available at depressed valuations. The goal in each investment is to work productively with management and/or the company's board to implement a strategy or strategies that maximize returns for all shareholders. ValueAct Capital is typically one of the largest independent shareholders at each of its core company investments and works in a constructive manner with management and/or the company's board to successfully implement strategies that generate superior returns on invested capital. The seven investment partners have extensive experience working effectively with portfolio companies as long-term large shareholders, and oftentimes as members of the companies' boards. At any given time, the portfolio consists of ten to eighteen core company investments, as well as a small "farm team" of additional investments in development.

Analyst
2009 - 2010

Strategic Value Capital focuses on long/short investments in the stocks of small- and mid-cap companies

Senior Associate & Principal
2007 - 2010

The Parthenon Group LLC provided strategic advisory and principal investment services. The company had offices in Boston, London, and San Francisco. The Parthenon Group was founded by William Achtmeyer and John Rutherford in 1991 and was headquartered in Boston, MA.

Boards & Committees
Independent Director
2015 - Current

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Independent Director
2015 - 2016

MSCI is a leading provider of investment decision support tools to around 7,500 clients worldwide, ranging from large pension plans to boutique hedge funds. We offer a range of products and services - including indices, portfolio risk and performance analytics, and governance tools - from a number of internationally recognized brands such as Barra, RiskMetrics, IPD and ISS. Located in 22 countries around the world, and, with over 2,700 employees, MSCI is dedicated to supporting the increasingly complex needs of the investment community with groundbreaking new products, high quality data, superior distribution and dedicated client support. Since the MSCI indices were launched over 40 years ago, the company has grown both organically and through acquisition to become one of the world’s leading players in the provision of products and services to institutional investors.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David Robert Hale. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David Robert Hale's profile does not indicate a business or promotional relationship of any kind between RelSci and David Robert Hale.